<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62199">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065336</url>
  </required_header>
  <id_info>
    <org_study_id>Heparc-2001</org_study_id>
    <nct_id>NCT02065336</nct_id>
  </id_info>
  <brief_title>Study of ARC-520 in Patients With Chronic Hepatitis B Virus</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arrowhead Research Corporation</source>
  <oversight_info>
    <authority>Hong Kong: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ARC-520 in combination with entecavir is
      effective in the treatment of patients with Chronic Hepatitis B Virus (HBV) Infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with ARC-520 for injection is expected to reduce all HBV proteins and replicative
      intermediates via RNA interference. The magnitude of the reduction and duration of effect
      will depend on the dose. Since to date ARC-520 has not been administered to patients with
      chronic HBV infection, the effective therapeutic dose in patients with chronic HBV infection
      is unknown. This study is designed to assess the antiviral activity of ARC-520, especially
      it's effect on HBsAg, in patients with chronic HBV infection at different dose levels.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Depth and duration of HBsAg reduction as a measure of efficacy</measure>
    <time_frame>Through Day 85</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>ARC-520</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, intravenous administration of ARC-520</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator, Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, intravenous administration of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-520</intervention_name>
    <arm_group_label>ARC-520</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Comparator, Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Have a diagnosis of HBeAg negative, immune active, chronic HBV infection and all of
             the following:

               1. History of being HBsAg positive at 2 time points &gt; 6 months apart

               2. HBsAg titer &gt; 1,000 IU/mL determined at screening

               3. HBeAg negative at screening

               4. HBV DNA &lt; 200 IU/mL at screening

          -  Patients with &gt; 6 months of continuous, 0.5 mg/day oral entecavir, and a willingness
             to continue taking entecavir throughout the study.

        Key Exclusion Criteria:

          -  Female patients that have a positive pregnancy test or are lactating.

          -  Acute signs of hepatitis/other infection (eg, moderate fever, jaundice, nausea,
             vomiting, and abdominal pain) evident within 4 weeks of screening and/or at the
             screening examination.

          -  Hepatic transaminases (ALT or AST) &gt; 100 IU/mL at screening.

          -  Patients with antiviral therapy other than entecavir within 3 months of screening or
             prior treatment with interferon or a toll receptor agonist in the last 5 years.

          -  Use within the last 6 months or an anticipated requirement for anticoagulants,
             corticosteroids, immunomodulators, or immunosuppressants.

          -  Has any history of autoimmune disease especially autoimmune hepatitis.

          -  Has human immunodeficiency virus (HIV) infection, as shown by the presence of
             anti-HIV antibody (sero-positive).

          -  Is sero-positive for HCV, and/or a history of delta virus hepatitis.

          -  Has a history of allergy to bee venom or history of hypersensitivity reaction
             requiring an emergency visit to a physician or hospital and/or requirement for
             treatment with steroids and/or epinephrine.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Given, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arrowhead Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Winnie Leung</last_name>
    <phone>+ 852 9646-3894</phone>
    <email>Winnie.Leung@iconplc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diamond Martin</last_name>
    <phone>+1 626 696 4704</phone>
    <email>dmartin@arrowres.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ringo Wu</last_name>
      <phone>+852 2255-3579</phone>
      <email>rchwu@hkucc.hku.hk</email>
    </contact>
    <investigator>
      <last_name>Man-Fung Yuen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Chim</last_name>
      <phone>+852 2632-3759</phone>
      <email>angelchim@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Henry Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 25, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
